lunes, 13 de noviembre de 2017

Molecular Testing of Lung Cancers. - PubMed - NCBI

Molecular Testing of Lung Cancers. - PubMed - NCBI



 2017 May;51(3):242-254. doi: 10.4132/jptm.2017.04.10. Epub 2017 Apr 21.

Molecular Testing of Lung Cancers.

Abstract

Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories-mutations, gene rearrangements, and amplifications-and propose expanded guidelines on molecular testing of lung cancers.

KEYWORDS:

Guideline; Lung neoplasms; Molecular testing; Precision medicine

PMID:
 
28427247
 
PMCID:
 
PMC5445209
 
DOI:
 
10.4132/jptm.2017.04.10

No hay comentarios:

Publicar un comentario